News
- Author:
- Neil Osterweil
Publish date: June 18, 2019
AMSTERDAM – The combination thwarts a mechanism that non-Hodgkin lymphomas use to evade immune surveillance.
News
- Author:
- Neil Osterweil
Publish date: June 18, 2019
AMSTERDAM – The telomerase inhibitor may also have disease-modifying properties, investigators suspect.
News
- Author:
- Neil Osterweil
Publish date: June 14, 2019
AMSTERDAM – The investigational agent may have disease modifying effects, researchers reported.
News
- Author:
- Neil Osterweil
Publish date: June 11, 2019
CHICAGO – About one-fifth of patients with resectable non–small cell lung cancer had major pathological responses with atezolizumab monotherapy pri...
News
- Author:
- Neil Osterweil
Publish date: June 11, 2019
CHICAGO – Among patients who went on to resection, 44% of those who had received neoadjuvant nivolumab and ipilimumab had a major pathological resp...
Video
- Author:
- Neil Osterweil
Publish date: June 5, 2019
CHICAGO – A proof-of-concept study suggests that broader inclusion criteria could nearly double participation in clinical trials for non–small cell...
Video
- Author:
- Neil Osterweil
Publish date: June 3, 2019
CHICAGO – The investigational drug showed encouraging responses in patients with heavily pretreated locally advanced ...
Video
- Author:
- Neil Osterweil
Publish date: June 3, 2019
The gap in timely access to care between African Americans and whites diagnosed with advanced solid tumors disappeared with the Affordable Care Act...
News
- Author:
- Neil Osterweil
Publish date: June 2, 2019
CHICAGO – Adding apalutamide to androgen deprivation therapy significantly improved overall survival of castration-se...
News
- Author:
- Neil Osterweil
Publish date: June 2, 2019
CHICAGO – Adding ribociclib to an aromatase inhibitor or tamoxifen was associated with an 29% relative reduction in r...
Video
- Author:
- Neil Osterweil
Publish date: June 1, 2019
CHICAGO – The overall survival rate at 42 months was 70% in the combined therapy group, vs. 46% for patients treated ...
News
- Author:
- Neil Osterweil
Publish date: June 1, 2019
CHICAGO – 10-year metastasis-free survival was superior for patients who received goserelin plus radiation for rising...
News
- Author:
- Neil Osterweil
Publish date: May 15, 2019
Missing efficacy data from the pivotal ENLIVEN trial and adverse liver events were points of contention.
News
- Author:
- Neil Osterweil
Publish date: May 14, 2019
SILVER SPRING, MD. – A small clinical benefit, questions about the validity of the data, and concerns about cardiovascular adverse events point to ...
News
- Author:
- Neil Osterweil
Publish date: April 30, 2019
ATLANTA – Nine of 10 patients in a phase 1/1b trial had pathologic complete responses to neoadjuvant nivolumab and radiation.
